Previous 10 | Next 10 |
2023-11-28 11:23:14 ET More on SciSparc Ltd. Clearmind, SciSparc slide amid weight-loss study results SciSparc initiates clinical study of CBD-based drug for autism symptoms Financial information for SciSparc Ltd. For further details see: SciSparc stock s...
2023-11-28 10:17:41 ET More on Clearmind Medicine Inc., SciSparc Ltd., etc. SciSparc initiates clinical study of CBD-based drug for autism symptoms SciSparc set to merge with a vehicle importer firm in Israel Financial information for Clearmind Medicine Inc. ...
Results from pre- clinical trial indicate potential effect in various metabolic parameters including fat oxidation, weight loss and reduced appetite Tel Aviv, Israel / Vancouver, Canada, Nov. 28, 2023 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq, CSE: CMND), (FSE: CWY) (“Clearmi...
Clearmind Medicine CEO, Dr. Adi Zuloff-Shani, and MAPS founder and psychedelic sector pioneer, Rick Doblin, will discuss the growing and changing international psychedelic space Tel Aviv, Israel / Vancouver, Canada, Nov. 27, 2023 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq, CSE: CMN...
2023-11-21 09:18:51 ET More on Clearmind Medicine Inc. Clearmind Medicine announces receipt of Nasdaq delisting notice Clearmind Medicine sinks 54%, prices $2.25M offering Financial information for Clearmind Medicine Inc. For further details see: Clearmin...
Following the reverse share split, the Company will have 607,381 Ordinary Shares issued and outstanding Tel Aviv, Israel / Vancouver, Canada, Nov. 21, 2023 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq, CSE: CMND), (FSE: CWY) (“Clearmind” or the "company"), a biotech compa...
2023-11-17 16:22:43 ET More on Clearmind Medicine Inc. Clearmind Medicine sinks 54%, prices $2.25M offering Financial information for Clearmind Medicine Inc. For further details see: Clearmind Medicine announces receipt of Nasdaq delisting notice
As part of the Company’s plan for recompliance, the Company’s shareholders approved a reverse stock split on November 14, 2023. Tel Aviv, Israel / Vancouver, Canada, Nov. 17, 2023 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq, CSE: CMND), (FSE: CWY) (“Clearmind ...
Company entered a Clinical Trial Agreement with Johns Hopkins University School of Medicine and Yale University to conduct its first in-human clinical trial Tel Aviv, Israel / Vancouver, Canada, Nov. 09, 2023 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. is pleased to announce...
Tel Aviv, Israel / Vancouver, Canada, Oct. 05, 2023 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq, CSE: CMND), (FSE: CWY) (“Clearmind” or the "company"), a biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-treat...
News, Short Squeeze, Breakout and More Instantly...
A look at the top 10 most actives in the United States Yoshitsu Co. Ltd (TKLF) rose 103.4% to $0.623 on volume of 309,019,720 shares Maxeon Solar Technologies Ltd. (MAXN) rose 11.2% to $0.2524 on volume of 226,231,487 shares NVIDIA Corporation (NVDA) fell 1.6% to $126.36 on volume of 208,...
Vancouver, Canada, July 16, 2024 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the "Company"), a clinical-stage biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-treated healt...
TEL AVIV, Israel, July 16, 2024 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) ("Company" or "SciSparc"), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders and rare diseases of the central nervous system, announced that an additional p...